预约演示
更新于：2025-03-30
Neostigmine Bromide
溴新斯的明
更新于：2025-03-30
概要
基本信息
结构/序列
分子式C12H19BrN2O2 |
InChIKeyLULNWZDBKTWDGK-UHFFFAOYSA-M |
CAS号114-80-7 |
关联
52
项与 溴新斯的明 相关的临床试验NCT06685705
Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl As Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries
CTRI/2023/07/055054
Effect of neostigmine on attenuation of proinflammatory cytokines secretion when given as an adjunctive therapy in septic shock: A Randomized controlled trial - NIL
PACTR202304565008785
Intramuscular Neostigmine and Postoperative Urinary Retention After Spinal Anesthesia for knee Arthroscopy, a Prospective Randomized Controlled Study
100 项与 溴新斯的明 相关的临床结果
登录后查看更多信息
100 项与 溴新斯的明 相关的转化医学
登录后查看更多信息
100 项与 溴新斯的明 相关的专利（医药）
登录后查看更多信息
3,913
项与 溴新斯的明 相关的文献（医药）2025-05-01DYES AND PIGMENTS
Rational design of fast-responding and highly selective fluorescent probes for detecting and imaging acetylcholinesterase homeostatic changes in Alzheimer's disease
作者: Ullah, Inam ; Shao, Yiwen ; Shen, Jiawen ; Zhang, Chenrun ; Zhu, Hai-Liang
Alzheimer′s disease (AD) is a progressive amnestic cognitive deteriorating neurodegenerative disease.Acetylcholinesterase (AChE) has a very high catalytic hydrolysis efficiency, which can rapidly hydrolyze acetylcholine into choline, playing a critical role in regulating the nervous system.Therefore, we designed and synthesized a fluorescent probe capable of quant. detecting AChE called ACP.Most strikingly, an extremely low detection limit of 0.341U/mL is far superior to those of many probes.The approach of utilizing ACP enabled us to swiftly identify and track real-time alterations in intracellular AChE levels.Addnl., our study marks the pioneering use of ACP in effectively detecting an increase in AChE expression in C. elegans and mice models of Alzheimer′s disease (AD).In conclusion, this study provides a new tool for quant. detecting AChE levels and shows great potential for application in AChE-related studies.
2025-03-01OBESITY SURGERY
Effect of Sugammadex on Post-operative Urinary Retention After Bariatric Surgery
Article
作者: Rosenbluth, Amy ; Spaniolas, Konstantinos ; Smolkin, Caroline ; Swaszek, Luke ; Crosby, Patrick ; Fuller, Samantha ; Sanicola, Caroline ; Pryor, Aurora
BACKGROUND:
The incidence of post operative urinary retention (POUR) after bariatric surgery has been described to be anywhere between 5 and 8%. This incidence is thought to be related in part to medications for neuromuscular blockade (NMBA) reversal. The purpose of this study was to determine the difference between sugammadex and neostigmine with an antimuscarinic agent on reducing POUR in bariatric patients.
METHODS:
Single center, retrospective, cohort, chart review study performed at a single academic institution. Patients who underwent primary laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LGBP) and were administered NMBAs, with subsequent reversal with either neostigmine with an antimuscarinic agent (N = 121) or with sugammadex (N = 107), formed the cohort. POUR was defined as the inability to void post-operatively within 6 h, requiring eventual urinary straight catheterization or placement of an indwelling urinary catheter at any time before discharge.
RESULTS:
A total of 7.9% developed POUR following bariatric surgery. The incidence of POUR was significantly lower in the sugammadex group when compared to the neostigmine group (1.9% vs 13.2%, p < 0.001). The length of stay was also significantly shorter in the sugammadex group when compared to the neostigmine group (1.7 (SD 0.7) vs 1.9 days (SD 0.6), p < 0.001). There was no significant difference in the rate of readmission (4.1% vs 3.7%, p = 0.561) or emergency department visits (10.7% vs 10.3%, p = 0.564). Multivariable regression demonstrated that sugammadex use was independently associated with a lower likelihood of developing POUR after surgery (OR 0.127 (95% CI 0.028-0.586), p = 0.008).
CONCLUSION:
The rate of POUR after bariatric surgery was significantly lower in the patients undergoing NMBA reversal with sugammadex when compared to neostigmine. This group also experienced a shorter length of stay.
2025-03-01Journal of Evidence Based Medicine
Pharmacological Interventions for Acute Pancreatitis in Adults: An Overview of Systematic Reviews
Review
作者: Sun, Xin ; Ding, Ling ; He, Qiao ; Wang, Wen ; Sun, Che ; Jian, Linge ; Xu, Jiayue ; Wang, Yuning
ABSTRACT:
Aim:
To provide a comprehensive assessment of the efficacy and safety of pharmacological interventions for AP.
Methods:
This was an overview of systematic reviews based on randomized controlled trials comparing pharmacological interventions with placebo or blank control in adults with AP. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to January 13, 2024, with an update on February 4, 2025. The effect value of each medication on each outcome of interest defined as a “combo” was assessed. Findings were categorized as efficacious, not efficacious, or inconclusive.
Results:
Fifteen reviews (167 unique trials, 12,930 participants) reported the efficacy of 14 medications on 5 outcomes, yielding 35 distinct combos. Seven combos showed efficacy with low certainty evidence: low molecular weight heparin (risk ratio 0.31, 95% confidence interval, 0.18–0.51), omega‐3 fatty acids (0.30, 0.14–0.65), and antioxidants (0.69, 0.49–0.98) for mortality; low molecular weight heparin (0.38, 0.22–0.65), chengqi‐series decoctions (0.48, 0.36–0.63), and ulinastatin (0.43, 0.24–0.78) for multiple organ failure; and neostigmine (mean difference –2.81, 95 % confidence interval –3.75 to –1.87) for length of intensive care unit stay. Half of the remaining combos showed no efficacy, while the other half was inconclusive for very low certainty evidence. Safety data were limited, with one review reporting no significant adverse events for neostigmine.
Conclusions:
Some pharmacological interventions exhibited potential efficacy for specific AP outcomes, albeit with low certainty evidence. Further verifying those medications is crucial in advancing the treatment landscape for AP.
100 项与 溴新斯的明 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性胃炎 | 日本 | 1956-04-14 | |
| 功能性便秘 | 日本 | 1956-04-14 | |
| 排尿困难 | 日本 | 1956-04-14 | |
| 重症肌无力 | 日本 | 1956-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 80 | (Neostigmine) | 齋夢醖壓觸積艱壓構艱(簾夢齋築鬱遞簾獵壓遞) = 願鏇窪襯遞積窪鏇醖衊 窪觸艱願選願膚壓襯齋 (淵憲膚窪範艱艱鬱膚淵, 簾鏇蓋夢鹽蓋壓壓獵製 ~ 製積艱選餘製襯夢壓膚) 更多 | - | 2020-05-22 | ||
(Sugammadex) | 齋夢醖壓觸積艱壓構艱(簾夢齋築鬱遞簾獵壓遞) = 廠衊顧襯選觸膚觸選積 窪觸艱願選願膚壓襯齋 (淵憲膚窪範艱艱鬱膚淵, 夢夢夢憲鏇築壓遞鑰鹹 ~ 積衊齋餘膚艱製獵顧簾) 更多 | ||||||
临床3期 | 75 | placebo+Single rocuronium dose (Single Rocuronium Dose - Placebo) | 願廠繭壓夢選餘鹹觸廠(壓膚齋糧鹹簾繭壓艱鹹) = 築鹹鏇鏇遞獵選製範選 糧膚蓋鹹構廠繭襯鑰憲 (鏇製製觸夢艱廠遞製壓, 衊窪衊膚簾選鏇膚積膚 ~ 願繭築蓋憲構簾觸顧鏇) 更多 | - | 2018-10-24 | ||
(Single Rocuronium Dose - Sugammadex) | 願廠繭壓夢選餘鹹觸廠(壓膚齋糧鹹簾繭壓艱鹹) = 遞襯築齋衊遞網顧餘糧 糧膚蓋鹹構廠繭襯鑰憲 (鏇製製觸夢艱廠遞製壓, 遞鏇鏇醖鹹遞獵窪窪醖 ~ 構憲襯壓網鏇蓋膚壓襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用